New Study Introduces Augmented Reality in Prostate Cancer Biopsies for Enhanced Accuracy

In a pioneering study titled "Targeted Augmented Reality-Guided Transperineal Prostate Biopsies," researchers Shenthiuiyan Theivendrampillai, Bob Yang, Mark Little, and Christopher Blick have introduced a groundbreaking approach to diagnosing prostate cancer. Utilizing the Virtual Surgery Intelligence (VSI) Holomedicine platform by apoqlar, this method combines mixed reality (MR) and augmented reality (AR) technologies to enhance the precision and safety of prostate biopsies.

Traditionally, transperineal biopsy under the guidance of magnetic resonance imaging (MRI) has been the gold standard in detecting prostate lesions indicative of cancer. The innovative approach taken in this study involves converting multiparametric prostate MRI images into 3D holograms, which are then superimposed onto the patient's body in a mixed reality space using Microsoft's HoloLens II system. This allows for a more accurate placement of biopsy needles, potentially increasing the procedure's effectiveness.

The "Targeted Augmented Reality-GuidEd Transperineal" (TARGET) study evaluated the feasibility of this novel technique in ten patients with clinically suspected prostate cancer, as indicated by high PI-RADS (Prostate Imaging-Reporting and Data System) scores. The patients underwent the MR/AR-guided biopsies using the PrecisionPoint Freehand transperineal system, followed by standard cognitive fusion biopsies for comparison.

The study's results were promising, with successful MR/AR-guided biopsies performed on all participants, yielding prostatic tissue samples in every case. Histological analysis showed a 70% match between the MR/AR-guided biopsies and the standard biopsies, with no immediate complications reported.

This initial exploration into MR/AR-assisted prostate biopsies suggests a significant advancement in prostate cancer diagnostics. The integration of real-time needle tracking and further investigation into the technique's sensitivity and specificity are anticipated as the next steps. This innovative approach could redefine how medical practitioners diagnose and treat prostate cancer, offering a less invasive and more accurate method for patients worldwide.

Link to the study:Read More

Contact us

Contact Form




If you send us your registration via the registration form, your details from the inquiry form, including the contact details you provided there, will be stored in order to process the request and in case of follow-up questions. We will not share this information without your consent. Your consent is voluntary and you can do so at any time by a simple statement (by e-mail, by mail to RPP GROUP SPRL, Rue Guimard 10, 1040 Brussels, Belgium).


Cookie settings

We use cookies on (e.g. tracking and analytical cookies), with which an analysis and measurement of user data is possible. Further information can be found in the